Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Jul 4, 2021

F ORM 4
---------------	--

[ ] Check this box if no longer subject to Section 16. Form 4 or continue. See Instruction 1(b).

FORM 4 Washington, D.C. 20549

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Form 5 obligations may UNITED STATES SECURITIES AND EXCHANGE COMMISSION STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES OMB APPROVAL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer
Amin Dipti (Last) (First) (Middle)	Lineage Cell Therapeutics, Inc. [ LCTX ] 3. Date of Earliest Transaction (MM/DD/YYYY)	(Check all applicable) X Director _ 10% Owner Officer (give title below) __ Other (specify below)
C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200	7/1/2021
(Street) CARLSBAD, CA 92008 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security 2. Trans. Date 2A. Deemed 3. Trans. Code 4. Securities Acquired (A) 5. Amount of Securities Beneficially Owned 6. 7. Nature (Instr. 3) Execution (Instr. 8) or Disposed of (D) Following Reported Transaction(s) Ownership of Indirect Date, if any (Instr. 3, 4 and 5) (Instr. 3 and 4) Form: Beneficial Direct (D) Ownership or Indirect (Instr. 4) (A) or (I) (Instr.
		Code	V	Amount	(D)	Price	4)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate	2.	3. Trans.	3A. Deemed	4. Trans. Code		5. Number of		6. Date Exercisable and		7. Title and Amount of		8. Price of	9. Number of	10.	11. Nature
Security	Conversion	Date	Execution	(Instr. 8)		Derivative Securities		Expiration Date		Securities Underlying		Derivative	derivative	Ownership	of Indirect
(Instr. 3)	or Exercise		Date, if any			Acquired (A) or				Derivative Security		Security	Securities	Form of	Beneficial
	Price of					Disposed of (D)				(Instr. 3 and 4)		(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					(Instr. 3, 4 and 5)							Owned	Security:	(Instr. 4)
	Security			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)
Stock Option (right to buy)	\$2.86	7/1/2021		A		50000		(1)	7/1/2031	Common Shares	50000	\$0	50000	D

Explanation of Responses:

(1) Will vest and become exercisable on July 1, 2022, subject to the reporting person's continuous service with the issuer.

Reporting Owners

	Relationships
Reporting Owner Name / Address	Director	10% OwnerOfficerOther
Amin Dipti C/O LINEAGE CELL THERAPEUTICS
2173 SALK AVENUE, SUITE 200	X
CARLSBAD, CA 92008

Signatures

/s/ Grant Harbert, as Attorney-in-Fact 7/1/2021

\\Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.